LAZCLUZE

This brand name is authorized in United States. It is also authorized in Austria, France, Lithuania.

Active ingredients

The drug LAZCLUZE contains one active pharmaceutical ingredient (API):

1	Lazertinib UNII 4A2Y23XK11 - LAZERTINIB
	Lazertinib is an irreversible EGFR tyrosine kinase inhibitor (TKI). It selectively inhibits both primary activating EGFR mutations (exon 19 deletions and exon 21 L858R substitution mutations) and the EGFR T790M resistance mutation, while having less activity against wild-type EGFR.
	Read more about Lazertinib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LAZCLUZE Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01EB09		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
Discover more medicines within L01EB09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
FR	Base de données publique des médicaments	65773151, 68660721
LT	Valstybinė vaistų kontrolės tarnyba	1102454, 1102455, 1102456, 1102457, 1102458, 1102459
US	FDA, National Drug Code	57894-080, 57894-240